Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KZIA
HoldKazia Therapeutics Limited · Healthcare · Australia · $155M · Avg Vol: $3M/d
36
StockRankGet insider-trade alerts
Q
40
V
22
M
64
P/E (TTM)
—
ROE
-106.9%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.7M | 30.1K | -98.2% | 1.4M |
| EPS | -164.25 | -160.84 | -1.68 | -959.14 | — | -7.62 |
| Shares | 11.4M | 11.4M | 11.4M | 11.4M | 0.0% | 11.4M |
| Debt | 1.3M | 1.3M | 0.5M | 0.3M | -40.1% | 71.0K |
| Equity | 13.1M | 8.6M | -7.2M | -5.9M | -34.1% | — |
| Op CF | -16.3M | -10.9M | -6.9M | -9.5M | — | -10.3M |
| Inv CF | -1.7M | 0 | 0 | — | — | — |
| Fin CF | 2.7M | 9.3M | 4.3M | 11.5M | — | — |
Loading 1Y...
PRICE (1Y)+0.2%
SMA 50SMA 200
Close
$13.58
RSI (14)
48.3
52W High
$17.40
From 52W High
0.8%
SCORE BREAKDOWN
Quality
40
ROIC (ROA)
-25.7%*27.9
ROE
-106.9%9.5
GP/Assets
32.6%69.5
Op. Margin
-14641.0%1.7
FCF/Assets
n/mN/A
Piotroski
325.3
Int. Cover
—N/A
D/E Ratio
0.00x91.7
Current Ratio
2.87x52.7
Value
22
P/E (TTM)
—N/A
EV/EBITDA
-7.5x25.0
P/FCF
n/mN/A
P/B
6.9x19.6
P/S
122.3x6.9
Div Yield
—N/A
Momentum
64
52W High %
78%62.1
RS 6M
48%90.4
SMA 50/200
1.30x93.4
EPS Rev 4W
-2.5%19.8
EPS Rev 12W
—N/A
EPS Improve
+100%74.4
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$155M
P/E (Forward)
-934.0x
Gross Margin
100.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KZIA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KZIA | Kazia Therapeutics Limited(you) | $155M | 36 | Hold |
| TTX.AX | Tetratherix Limited | $263M | 34 | Sell |
| ATH.AX | Alterity Therapeutics Limited | $81M | 28 | Sell |
| SPL.AX | Starpharma Holdings Limited | $244M | 49 | Hold |
| OCC.AX | Orthocell Limited | $147M | 14 | Strong Sell |
| AVE.AX | Avecho Biotechnology Limited | $64M | 42 | Hold |
| ACW.AX | Actinogen Medical Limited | $118M | 18 | Strong Sell |
| NYR.AX | Nyrada Inc. | $147M | 13 | Strong Sell |
| ILA.AX | Island Pharmaceuticals Limited | $93M | 19 | Strong Sell |
| ATX.AX | Amplia Therapeutics Limited | $53M | 30 | Sell |
Peer medians: ROE -20.6% · P/E 34.6x · Gross margin 61.1%